Valuation Metrics and Recent Changes
As of 24 March 2026, Fredun Pharmaceuticals trades at a price of ₹1,686.30, up 2.15% from the previous close of ₹1,650.85. The stock has a 52-week high of ₹1,999.00 and a low of ₹635.05, reflecting significant volatility but an overall upward trajectory. The recent valuation grade adjustment from attractive to fair is primarily driven by the current price-to-earnings (P/E) ratio of 27.69 and a price-to-book value (P/BV) of 5.74. These figures indicate a premium relative to historical averages and peer benchmarks, signalling a moderation in price attractiveness.
Fredun’s enterprise value to EBITDA (EV/EBITDA) ratio stands at 12.84, which is competitive within its sector but slightly elevated compared to some peers. The company’s PEG ratio of 0.45 remains low, suggesting that earnings growth expectations are still reasonably priced into the stock. However, the shift in valuation grade reflects a cautious stance given the premium multiples relative to micro-cap norms.
Comparative Peer Analysis
When benchmarked against key competitors in the Pharmaceuticals & Biotechnology space, Fredun Pharmaceuticals’ valuation metrics present a mixed picture. For instance, Bliss GVS Pharma, rated as fair, trades at a P/E of 18.58 and EV/EBITDA of 13.56, indicating a more conservative valuation. Meanwhile, Shukra Pharma is classified as very expensive with a P/E of 53.5 and EV/EBITDA of 43.86, underscoring the wide valuation spectrum within the sector.
Other peers such as Kwality Pharma and Jagsonpal Pharma also command expensive valuations, with P/E ratios of 26.44 and 28.73 respectively, and elevated EV/EBITDA multiples. This context places Fredun Pharmaceuticals in a middle ground, where its fair valuation grade reflects a balance between growth potential and price caution.
Financial Performance and Quality Metrics
Fredun Pharmaceuticals boasts robust financial health, with a return on capital employed (ROCE) of 20.23% and return on equity (ROE) of 21.61%, both indicative of efficient capital utilisation and strong profitability. The company’s dividend yield remains minimal at 0.04%, consistent with growth-oriented firms that prioritise reinvestment over shareholder payouts.
Enterprise value to capital employed (EV/CE) at 3.34 and EV to sales at 1.80 further highlight the company’s operational efficiency relative to its valuation. These metrics, combined with a PEG ratio below 0.5, suggest that while the stock is no longer deemed highly attractive on valuation grounds, it still offers reasonable value given its growth prospects and profitability.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Stock Performance Relative to Sensex
Fredun Pharmaceuticals has demonstrated remarkable stock price appreciation relative to the benchmark Sensex index. Over the past year, the stock has surged by 141.12%, vastly outperforming the Sensex’s decline of 5.47%. Even on a three-year basis, Fredun has delivered a 104% return compared to the Sensex’s 25.50%, and over five years, the stock’s 267.43% gain dwarfs the benchmark’s 45.24% rise.
Shorter-term returns also reflect resilience, with a one-week gain of 4.49% against a Sensex drop of 3.72%, and a year-to-date return of 6.84% while the Sensex fell 14.70%. These figures underscore the stock’s strong momentum and investor confidence despite the recent valuation moderation.
Market Capitalisation and Risk Considerations
Fredun Pharmaceuticals remains classified as a micro-cap stock, which inherently carries higher volatility and liquidity risk compared to larger peers. The company’s Mojo Score of 74.0 and upgraded Mojo Grade from Hold to Buy as of 29 July 2025 reflect positive analyst sentiment and improved fundamentals. This upgrade signals growing conviction in the company’s growth trajectory and operational execution.
However, investors should remain mindful of the elevated P/BV ratio of 5.74, which is high relative to typical micro-cap valuations, and the modest dividend yield, which may limit income appeal. The EV to EBIT ratio of 13.84 also suggests that the stock is priced with expectations of sustained earnings growth, which will need to be realised to justify current multiples.
Fredun Pharmaceuticals Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Outlook and Investor Takeaways
Fredun Pharmaceuticals’ transition from an attractive to a fair valuation grade reflects a maturing stock price that now incorporates much of the company’s growth potential. While the premium multiples warrant caution, the company’s strong returns, solid profitability metrics, and upgraded analyst rating provide a compelling case for continued investor interest.
Investors should weigh the stock’s micro-cap risks against its demonstrated ability to outperform the broader market and peers. The relatively low PEG ratio suggests that earnings growth remains a key driver and that the stock is not excessively overvalued on a growth-adjusted basis. However, monitoring future earnings delivery and sector developments will be critical to assessing whether the current fair valuation can evolve back towards attractiveness.
In summary, Fredun Pharmaceuticals offers a balanced investment proposition: a micro-cap stock with robust fundamentals and strong price momentum, tempered by valuation moderation and inherent sector risks. This nuanced profile makes it a noteworthy candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a growth orientation.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
